anti-TIGIT bispecific

AGEN1777 is a first-in-class TIGIT bispecific which targets a major inhibitory receptor expressed on T and NK cells to improve anti-tumor activity.

TIGIT is a negative regulator of innate and adaptive immune responses.

AGEN1777 is advancing as monotherapy and in combination with a PD-1 inhibitor in a clinical trial against solid tumors.

Latest Clinical Trials

Solid Tumors


Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with advanced, metastatic solid tumors